Report Detail

Request for Sample of this report

Pharma & Healthcare Global IL-17 Inhibitors for Psoriasis Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

  • RnM4736412
    • |
  • 24 August, 2026
    • |
  • Global
    • |
  • 101 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global IL-17 Inhibitors for Psoriasis market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
IL-17 inhibitors for psoriasis are a class of biologic drugs designed to target and block the activity of interleukin-17 (IL-17), a pro-inflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. By inhibiting IL-17, these drugs reduce the excessive immune response and help control the symptoms of moderate to severe plaque psoriasis. Examples of IL-17 inhibitors include secukinumab, ixekizumab, brodalumab and so on.
This report is a detailed and comprehensive analysis for global IL-17 Inhibitors for Psoriasis market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global IL-17 Inhibitors for Psoriasis market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global IL-17 Inhibitors for Psoriasis market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global IL-17 Inhibitors for Psoriasis market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global IL-17 Inhibitors for Psoriasis market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for IL-17 Inhibitors for Psoriasis
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global IL-17 Inhibitors for Psoriasis market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include UCB, Eli Lilly, Novartis, Ortho Dermatologics, LEO Pharma, Kyowa Kirin, Jiangsu Hengrui Pharmaceuticals, Chongqing Genrix Biopharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
IL-17 Inhibitors for Psoriasis market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Bimelizumab
Secukinumab
Ixekizumab
Brodalumab
Vunakizumab
Xeligekimab
Other
Market segment by Application
Hospital and Clinic
Pharmacy
Other
Major players covered
UCB
Eli Lilly
Novartis
Ortho Dermatologics
LEO Pharma
Kyowa Kirin
Jiangsu Hengrui Pharmaceuticals
Chongqing Genrix Biopharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe IL-17 Inhibitors for Psoriasis product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of IL-17 Inhibitors for Psoriasis, with price, sales quantity, revenue, and global market share of IL-17 Inhibitors for Psoriasis from 2021 to 2026.
Chapter 3, the IL-17 Inhibitors for Psoriasis competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the IL-17 Inhibitors for Psoriasis breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and IL-17 Inhibitors for Psoriasis market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of IL-17 Inhibitors for Psoriasis.
Chapter 14 and 15, to describe IL-17 Inhibitors for Psoriasis sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global IL-17 Inhibitors for Psoriasis Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Bimelizumab
    • 1.3.3 Secukinumab
    • 1.3.4 Ixekizumab
    • 1.3.5 Brodalumab
    • 1.3.6 Vunakizumab
    • 1.3.7 Xeligekimab
    • 1.3.8 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global IL-17 Inhibitors for Psoriasis Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital and Clinic
    • 1.4.3 Pharmacy
    • 1.4.4 Other
  • 1.5 Global IL-17 Inhibitors for Psoriasis Market Size & Forecast
    • 1.5.1 Global IL-17 Inhibitors for Psoriasis Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global IL-17 Inhibitors for Psoriasis Sales Quantity (2021-2032)
    • 1.5.3 Global IL-17 Inhibitors for Psoriasis Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 UCB
    • 2.1.1 UCB Details
    • 2.1.2 UCB Major Business
    • 2.1.3 UCB IL-17 Inhibitors for Psoriasis Product and Services
    • 2.1.4 UCB IL-17 Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 UCB Recent Developments/Updates
  • 2.2 Eli Lilly
    • 2.2.1 Eli Lilly Details
    • 2.2.2 Eli Lilly Major Business
    • 2.2.3 Eli Lilly IL-17 Inhibitors for Psoriasis Product and Services
    • 2.2.4 Eli Lilly IL-17 Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Eli Lilly Recent Developments/Updates
  • 2.3 Novartis
    • 2.3.1 Novartis Details
    • 2.3.2 Novartis Major Business
    • 2.3.3 Novartis IL-17 Inhibitors for Psoriasis Product and Services
    • 2.3.4 Novartis IL-17 Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Novartis Recent Developments/Updates
  • 2.4 Ortho Dermatologics
    • 2.4.1 Ortho Dermatologics Details
    • 2.4.2 Ortho Dermatologics Major Business
    • 2.4.3 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product and Services
    • 2.4.4 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Ortho Dermatologics Recent Developments/Updates
  • 2.5 LEO Pharma
    • 2.5.1 LEO Pharma Details
    • 2.5.2 LEO Pharma Major Business
    • 2.5.3 LEO Pharma IL-17 Inhibitors for Psoriasis Product and Services
    • 2.5.4 LEO Pharma IL-17 Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 LEO Pharma Recent Developments/Updates
  • 2.6 Kyowa Kirin
    • 2.6.1 Kyowa Kirin Details
    • 2.6.2 Kyowa Kirin Major Business
    • 2.6.3 Kyowa Kirin IL-17 Inhibitors for Psoriasis Product and Services
    • 2.6.4 Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Kyowa Kirin Recent Developments/Updates
  • 2.7 Jiangsu Hengrui Pharmaceuticals
    • 2.7.1 Jiangsu Hengrui Pharmaceuticals Details
    • 2.7.2 Jiangsu Hengrui Pharmaceuticals Major Business
    • 2.7.3 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product and Services
    • 2.7.4 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
  • 2.8 Chongqing Genrix Biopharmaceutical
    • 2.8.1 Chongqing Genrix Biopharmaceutical Details
    • 2.8.2 Chongqing Genrix Biopharmaceutical Major Business
    • 2.8.3 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product and Services
    • 2.8.4 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Chongqing Genrix Biopharmaceutical Recent Developments/Updates

3 Competitive Environment: IL-17 Inhibitors for Psoriasis by Manufacturer

  • 3.1 Global IL-17 Inhibitors for Psoriasis Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global IL-17 Inhibitors for Psoriasis Revenue by Manufacturer (2021-2026)
  • 3.3 Global IL-17 Inhibitors for Psoriasis Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of IL-17 Inhibitors for Psoriasis by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 IL-17 Inhibitors for Psoriasis Manufacturer Market Share in 2025
    • 3.4.3 Top 6 IL-17 Inhibitors for Psoriasis Manufacturer Market Share in 2025
  • 3.5 IL-17 Inhibitors for Psoriasis Market: Overall Company Footprint Analysis
    • 3.5.1 IL-17 Inhibitors for Psoriasis Market: Region Footprint
    • 3.5.2 IL-17 Inhibitors for Psoriasis Market: Company Product Type Footprint
    • 3.5.3 IL-17 Inhibitors for Psoriasis Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global IL-17 Inhibitors for Psoriasis Market Size by Region
    • 4.1.1 Global IL-17 Inhibitors for Psoriasis Sales Quantity by Region (2021-2032)
    • 4.1.2 Global IL-17 Inhibitors for Psoriasis Consumption Value by Region (2021-2032)
    • 4.1.3 Global IL-17 Inhibitors for Psoriasis Average Price by Region (2021-2032)
  • 4.2 North America IL-17 Inhibitors for Psoriasis Consumption Value (2021-2032)
  • 4.3 Europe IL-17 Inhibitors for Psoriasis Consumption Value (2021-2032)
  • 4.4 Asia-Pacific IL-17 Inhibitors for Psoriasis Consumption Value (2021-2032)
  • 4.5 South America IL-17 Inhibitors for Psoriasis Consumption Value (2021-2032)
  • 4.6 Middle East & Africa IL-17 Inhibitors for Psoriasis Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global IL-17 Inhibitors for Psoriasis Sales Quantity by Type (2021-2032)
  • 5.2 Global IL-17 Inhibitors for Psoriasis Consumption Value by Type (2021-2032)
  • 5.3 Global IL-17 Inhibitors for Psoriasis Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global IL-17 Inhibitors for Psoriasis Sales Quantity by Application (2021-2032)
  • 6.2 Global IL-17 Inhibitors for Psoriasis Consumption Value by Application (2021-2032)
  • 6.3 Global IL-17 Inhibitors for Psoriasis Average Price by Application (2021-2032)

7 North America

  • 7.1 North America IL-17 Inhibitors for Psoriasis Sales Quantity by Type (2021-2032)
  • 7.2 North America IL-17 Inhibitors for Psoriasis Sales Quantity by Application (2021-2032)
  • 7.3 North America IL-17 Inhibitors for Psoriasis Market Size by Country
    • 7.3.1 North America IL-17 Inhibitors for Psoriasis Sales Quantity by Country (2021-2032)
    • 7.3.2 North America IL-17 Inhibitors for Psoriasis Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe IL-17 Inhibitors for Psoriasis Sales Quantity by Type (2021-2032)
  • 8.2 Europe IL-17 Inhibitors for Psoriasis Sales Quantity by Application (2021-2032)
  • 8.3 Europe IL-17 Inhibitors for Psoriasis Market Size by Country
    • 8.3.1 Europe IL-17 Inhibitors for Psoriasis Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe IL-17 Inhibitors for Psoriasis Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific IL-17 Inhibitors for Psoriasis Market Size by Region
    • 9.3.1 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific IL-17 Inhibitors for Psoriasis Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America IL-17 Inhibitors for Psoriasis Sales Quantity by Type (2021-2032)
  • 10.2 South America IL-17 Inhibitors for Psoriasis Sales Quantity by Application (2021-2032)
  • 10.3 South America IL-17 Inhibitors for Psoriasis Market Size by Country
    • 10.3.1 South America IL-17 Inhibitors for Psoriasis Sales Quantity by Country (2021-2032)
    • 10.3.2 South America IL-17 Inhibitors for Psoriasis Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa IL-17 Inhibitors for Psoriasis Market Size by Country
    • 11.3.1 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa IL-17 Inhibitors for Psoriasis Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 IL-17 Inhibitors for Psoriasis Market Drivers
  • 12.2 IL-17 Inhibitors for Psoriasis Market Restraints
  • 12.3 IL-17 Inhibitors for Psoriasis Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of IL-17 Inhibitors for Psoriasis and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of IL-17 Inhibitors for Psoriasis
  • 13.3 IL-17 Inhibitors for Psoriasis Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 IL-17 Inhibitors for Psoriasis Typical Distributors
  • 14.3 IL-17 Inhibitors for Psoriasis Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on IL-17 Inhibitors for Psoriasis. Industry analysis & Market Report on IL-17 Inhibitors for Psoriasis is a syndicated market report, published as Global IL-17 Inhibitors for Psoriasis Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of IL-17 Inhibitors for Psoriasis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo